20% of nasopharyngeal cancer patients face recurrence and metastasis, immunotherapy may become a new "life-saving" method

According to statistics, half of the new cases of nasopharyngeal cancer in the world are in China.

The emergence of immune drugs is expected to change this situation.

EB virus positive = nasopharyngeal carcinoma?

There are obvious ethnic and regional differences in nasopharyngeal cancer.

In addition, Epstein-Barr virus infection can induce the occurrence of nasopharyngeal carcinoma.

Professor Hu Chaosu suggested that once the Epstein-Barr virus infection is found to be positive, blood should be drawn to check the VCA-IgA quantification.

Patients with advanced recurrence and metastasis of nasopharyngeal cancer finally "have medicines available"

Even if nasopharyngeal cancer is discovered, there is no need to panic.

But what needs to be noticed is that 10% of patients will still have recurrence, and 10%-20% of patients will have metastasis.

Fortunately, in December 2018, as my country’s first domestically produced anti-PD-1 monoclonal antibody drug, teriprizumab was approved for marketing.

Professor Mai Haiqiang, director of the Department of Nasopharyngology, Cancer Center, Sun Yat-sen University, pointed out: "The results of 92 cases in the POLARIS-02 study show that teriplizumab has brought longer survival to patients who have received first-line, second-line, or even third-line treatment.

It is reported that the objective response rate of teriprizumab monotherapy was 23.

Professor Hu Chaosu suggested that for keratinizing nasopharyngeal carcinoma, patients with nasopharyngeal carcinoma with a baseline LDH level ≤2xULN and a baseline EBV drop <10000IU/ML are more likely to benefit from immunotherapy.

At the same time, 39 Health learned that the JUPITER-02 study, with Professor Ruihua Xu as the main investigator, has also reached the main research endpoint.